| Description | 13-Methylberberine chloride shows anti-adipogenic effect on 3T3-L1 adipocytes, it has potential as an anti-obesity drug |
| In vitro | We screened 11 protoberberine and 2 benzophenanthridine alkaloids for their anti-adipogenic effects on 3T3-L1 adipocytes and found that 13-Methylberberine exhibited the most potent activity. 13-Methylberberine down-regulated the expression of the main adipocyte differentiation transcription factors, peroxisome proliferator-activated receptor gamma (PPARγ) and CCAAT enhancer binding protein alpha (C/EBPα±), as well as their target genes. PPARγ, C/EBPα±, and sterol regulatory element binding protein 1 (SREBP-1) protein levels were reduced, and this lipid-reducing effect was attenuated by an AMP-activated protein kinase (AMPK) inhibitor, indicating that the effect of this compound requires the AMPK signaling pathway. Decreased Akt phosphorylation suggested reduced de novo lipid synthesis. C-13 methyl substitution of berberine increased its accumulation in treated cells, suggesting that 13-Methylberberine has improved absorption and higher accumulation compared to berberine. |
| Synonyms | 13-甲基小檗碱, 13-Methylberberine |
| molecular weight | 385.84 |
| Molecular formula | C21H20ClNO4 |
| CAS | 54260-72-9 |
| Storage | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 10 mg/mL (25.92 mM) |
| References | 1. 13-Methylberberine, a berberine analogue with stronger anti-adipogenic effects on mouse 3T3-L1 cells.Sci Rep. 2016 Dec 5;6:38129. |